A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Novartis
Pfizer
Erasca, Inc.
Incyte Corporation
Allist Pharmaceuticals, Inc.
AstraZeneca
Pfizer
Quanta Therapeutics
R-Pharm
Genentech, Inc.
FBD Biologics Limited
Boehringer Ingelheim
Bristol-Myers Squibb
Pfizer
Bristol-Myers Squibb
Mirati Therapeutics Inc.
Pfizer
Quanta Therapeutics
MedImmune LLC
InventisBio Co., Ltd
Mirati Therapeutics Inc.
US Oncology Research
Ono Pharmaceutical Co., Ltd.